In addition, the immunohistochemical analysis indicated that FGFC1 treatment decreased the expression of Ki-67, a marker for tumor cell proliferation, and significantly reduced EGFR phosphorylation in tumor cells which were consistent with the in vitro study (Figures 6E,F). Here, EGFR is linked to neoplasm.